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Abstract
Xenotransplantation is a breakthrough medicinal technology that is an attempt to change the lives of millions of people. The
problems in the current organ transplant system risk the lives of patients each and every day. Intense waiting periods and
extremely costly procedures exemplify the stress and pressure that these patients face as an attempt to save their own lives.
Xenotransplantation is the idea of growing human organs in a different species, using incredible stem-cell and CRISPR technology.
This can introduce an answer to some of the issues in the current transplant system. Many technical and ethical issues are
becoming relevant with the introduction of this new medical phenomenon. If these barriers can be overcome, xenotransplantation
can offer a quicker, cheaper, and more effective option for patients in need of an organ transplant.
Introduction
Thousands of sick patients are in desperate need of an organ
transplant, often having their entire lives depending on this one
vital procedure. Before they can undergo treatment, a proper
organ donor must be found, and the process is harder than
ever imagined. Numerous factors affect the long waiting time, a
period that can frequently become over a year. The main slowdown is the simple shortage of organs ready for transplant. In
response to the overwhelming need for organ donations, new
medical research is being explored as an attempt to alleviate the
high demand. Xenotransplantation poses as a possible solution
to this problem and has the capabilities to be very helpful in the
medical world; releasing the great amount of stress and anxiety
involved in the classic organ transplant system that is now in
place. However, this new medical process introduces new biomedical and ethical issues. Scientists and doctors are currently
exploring the possibilities of this new technology, weighing the
costs against the benefits; an important attempt to improve the
medical world of organ transplantation.

History of Organ Transplants
The concept of organ transfer in a procedural sense has been
around for centuries, in-fact cases of organ transplantation dates
back to ancient times. There is even written proof and documentation from archeological records that suggest that organ
and tissue transplantation is thousands of years old. However,
modern-day organ transplantation is a relatively new medical
phenomenon that has saved the lives of millions of people from
end-stage organ failure.
In the early 1900’s, Dr. Alexis Carrel experimented with kidney transplantations in cats, becoming the first surgeon to explore vascular surgery (Howard et.al., 2012). Carrel’journey to
organ transplantations started with success in vascular surgery
and suturing of vessels. These experiments also advanced the
knowledge of organ preservation, showing that human tissue
could be stored in either saline solution, the patient’s serum,
or defibrinated blood, until it is needed. Carrel then went on
to organ transplantations, experimenting with kidney transplantations between dogs, and from dogs to cats. He realized that
the animals only lived with the transplant for a short period
of time and he knew that there was some sort of rejection
going on in the host’s body. Alexis Carrel made extraordinary

advancements in the medical exploration of organ transplants
and created the possibility for more research in this area
(Rothwell, 2011). In 1923, Dr. Harold Neuhof wrote a book
called The Transplantation of Tissues, which revealed the work
of many different tissue transplants including skin, cornea, muscle, pancreas and nerve tissue (Howard et.al., 2012).
Soon after, the first human kidney transplant was recorded
using a kidney from a donor that had died six hours prior. The
blood type of the donor was type B and the recipient was type
O, which prevented the kidney from functioning, leading to the
patient’s death. However, this may not have been the only cause
for the disfunction of the kidney as other trials have also been
proven unsuccessful. In 1953, a kidney transplant was done from
mother to son which only lasted three weeks before the recipient rejected the donor organ. In the beginning years of the
1950’s, Dr. David Hume performed almost ten kidney transplantations which are now considered the first of their kind in the
modern era of transplantation. However, none of the recipients
had a long-term survival after their kidney transplant.
These and other trials revealed that such organ transplants
would not be possible without immunosuppressant drugs. With
this development, organ transplant became a real option for
patients with organ failure. Dr. Joseph Murray performed the
first successful kidney transplant in 1962, leading into many
other victorious cases around the world. The ‘60’s were very
progressive years for this specific research and medication, as
the first lung and heart transplants were also done during this
time (Howard et. al., 2012).

Problems With the Current Organ Transplant
System
As immunosuppressant drugs allowed organ transplantation to
start becoming a viable option for victims of organ failure, the
need for transplantable organs became overwhelming. In the past,
kidneys from living donors were being used, but this supply is limited and not nearly enough to provide for all in need. Even with
deceased donors for transplants, the available donor organs, unfortunately, do not cover the demand (United Network for Organ
Sharing, Data, 2018).
Although most technical problems involved in the process have
been solved, organ transplantation is not seen as a long-term cure
for patients as there are still biological issues and financial problems.
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The biggest and most complicated problem is the patient’s
rejection of the new organ. When a patient undergoes an organ
transplant surgery, the body’s immune system becomes stimulated against the “foreign” organ and tries to kill it. Patients
are usually given strong medication to suppress their entire
immune system, but that can become counterproductive as the
patient is now vulnerable to other diseases. Different drugs,
such as Cyclosporin, have been approved to control much of
the rejection, but transplantations can still have those dangerous
effects (MTF Biologics, 2017). Although they have been shown
to improve symptoms, these drugs can have many negative side
effects including tremors and seizures.
Another problem is the long waiting period that patients wait
in order to receive a proper match for donation. There are simply not enough donors to fill the demands, causing many victims
to die in the ‘waiting room’. Although the shortage of organs is
the main cause for the waiting time, the length that the patient
waits can vary, depending on a number of factors. The blood or
tissue type, the size of the organ, and the medical urgency of the
situation are some factors that will fluctuate the waiting time. In
any case, the patient almost always needs to wait for a proper
donor before proceeding with the transplant.This is not practical
in many cases when the organ transplant is extremely urgent. On
average, twenty people die every day while waiting for an organ
donor (United Network for Organ Sharing, Data, 2018).
Also, organ transplants are extremely costly and many people
simply cannot afford such medical procedures. Kidney transplants cost over four hundred thousand dollars, and a heart
transplant goes up to over one million (Rapp & Vandermey,
2017). This cost does not even include the health maintenance
of such a procedure, nor the cost of immunosuppressant drugs
that cost as much as ten thousand dollars per year, for life
(Gordon, et. al. 2008).

Methodology of Xenotransplantation
Looking for a solution to this unmet medical need, researchers have come up with a new method known as
Xenotransplantation, which is the process of “grafting or transplanting organs or tissues between members of different species.” Xenotransplantation is using stem-cell and CRISPR technology to grow human organs in a host of a different species.
This idea comes from chimerism, the ability to create a “living
thing that is composed of cells from two or more organisms”
(Dunlap, 2017). The basic procedure is to use the pig as a host
by cutting out the HOX genes that code for growing certain
organs and the genes that code for porcine microorganisms
from their genome. HOX genes are the sequence of genes in
the genome that directs the body organization in an embryo
(KhanAcademy, Khanacademy.org, 2018). Using CRISPR-Cas9
technology, described below, genetic engineers can knock out
the genes in the pig that code for the development of specific
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organs, and replace them with specialized human stem cells that
will grow human organs instead. The hypothesis is that infusing
differentiated human stem-cells into this embryo will result in
the pig growing a human organ instead of its own.

CRISPR-Cas9 Technology
CRISPR-Cas9 stands for Clustered Regularly Interspaced Short
Palindromic Repeats, and is breakthrough technology in genome
editing. CRISPR is a special region in DNA that is characterized
by having repeated nucleotides and spacers. This unique DNA
region was first recognized in bacterial genomes and has since
been adapted in the laboratory as the CRISPR Cas9 complex
(Vidyasagar, 2018). Cas9 is a protein that acts as the molecular scissors that can cut the DNA in a double-strand break.
When combined with a guide RNA (sgRNA), it forms the Cas9
Complex. The Cas9 first binds to a sequence in the genome
and the guide RNA unwinds the double helix. The guide RNA
is precisely designed to match up with the specific strand of
DNA that needs to be edited. Then, the Cas9, with the help of
its nuclease domains, cuts the DNA, creating a double-strand
break in the double-helix. The DNA tries to repair itself but the
reparations are usually flawed which inevitably shuts off that
particular gene. This is why CRISPR is “a great tool for knocking
out specific genes” (NatureVideoChannel, 2017).

Stem-Cell Research
Another biomedical technique is somatic cell nuclear transfer,
known as SCNT, or cloning. Conceptually, the nucleus from a
somatic (body) cell replaces the nucleus in a fertilized oocyte of
another individual.This hybrid blastocyst is capable of generating
a stem cell line” (Columbia.edu, 2018). The created stem cells
will be identical to the donor and have many uses in the medical
field. One such example would be to use these cloned cells to
create human organs in pigs a step in the xenotransplantation
process. The idea is to fuse the stem cells from the patient into
a porcine embryo, hoping that the pig will grow human organs
that can then be used as the transplant for the intended patient.
In a few short months, the patient could potentially be on his/
her way to a complete recovery. This will only be a possibility,
however, if the barriers of Xenotransplantation are overcome.

Brief History of Xenotransplantation
Aside from cross-species blood transfusions, which were
around since the 17th century, skin grafts are considered the
first attempted trial in xenotransplantation. Skin grafts from animals to human patients were performed as early as the 19th
century. Frog skin was the most popular species to was the
most frequent source of the donor material to the skin grafts.
Different attempts at xenotransplantation were tested, mostly
using primates as the donor animal. Out of thirteen trials, only
one kidney transplant from a chimpanzee to a human patient
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was successful with the patient living for an entire nine months
before dying as a result of rejection of the kidney. In 1964,
the first heart xenograft from a chimpanzee to a human was
performed. The patient died within two hours of the operation.
Later, in 1992, a doctor named Starzl performed a baboon to
human liver transplant, with the patient surviving for seventy
days. Along with the numerous failures, some of the early xenotransplants resulted in temporary patient survival. But, in general, the organs were rejected in an even more serious case than
with a same-species transplant. The rejections of this kind are
so severe that immunosuppressive drugs are not strong enough
to stop the rejective response to the xenografts (Cooper, 2015)

The Advantages of Porcine Xenotransplantation
Recently, the focus has been on the use of organs from the pig
and hog family, porcine, as they are comparable to human organs in size, anatomy and physiology, compared to other species
(Niu, Wei, & Lin, 2017). Pigs, compared to other species such as
baboons, would be a valuable candidate for organ xenotransplantation. Pigs can be bred in large herds and with a relatively
short maternity period, making them a more available option. In
addition, they are not a costly animal to breed (Cooper, 2015).
The advantages of xenotransplantation from pigs would be
enormous, starting with the obvious increase in availability of
organs for transplantation. Right now, there is a shortage of
human organs for transplants, but using organs from another
species will solve this problem, it will also make immediate
transplant surgery possible for patients with an urgent situation.
In addition, organs that are retrieved from human cadavers have
already experienced the trauma of brain death which may lead
to other issues later on. With animal donor organs, the organs
will be removed from a healthy pig that is under anesthesia,
avoiding the problem altogether. Another important solution
that xenotransplantation brings is the decrease of the risk of
a pathogen being transferred from the donor to the patient.
Diseases such as the West Nile Virus and rabies have been
passed through organ transplant surgery resulting in a number
of deaths. The pigs intended to be used for xenotransplantation
are being raised in the best conditions and are being supervised
closely which reduces the likelihood of any illness to be transferred from donor to patient (Cooper, 2015).

Zoonoses and Porcine Endogenous Retrovirus
(PERV)
CRISPR-Cas9 can be used in xenotransplantation research by
knocking out specific genes in the pig that cause rejection when
transplanted into human patients. Zoonoses are diseases that
are transferred between humans and animals, caused by bacteria, parasites, and viruses. These diseases pose the major barrier preventing xenotransplantation from becoming proto-call
in the medical world. The potential transfer of porcine related

infections into the human genome is a major risk of xenotransplantation. The pig herds intended to be used for medical
reasons have been raised under the most sanitary conditions
and have been screened for most pathogens and viruses that
can possibly harm the recipient. However, porcine endogenous
retroviruses that lie in the porcine genome have the capability
to hurt human health. PERV are viral elements in the porcine
genome, and being that they are innately a part of the DNA, the
retroviruses cannot be eliminated by means of selective breeding or drugs. PERVs have the ability to recombine with other
genetic elements of the recipient’s genome. Similar to pigs, humans have their own set of endogenous retroviruses, known as
human endogenous retroviruses, or HERVs. If the PERV were to
come in contact with the human endogenous retroviruses, the
former genes can recombine and disturb the human genome.
Naturally, the HERVs are attempted to be halted by some sort
of stop codons or deletions, but some bypass the stop codons
and actually “play an important role in human physiology as well
as in pathogenesis” (Machnik, et al., 2014).
Studies of HERVs have concluded that class I of HERVS group
together with γ- and ε-retroviruses, and during a xenotransplantation it is these genes that can recombine with PERVs that
also belong to the γ-retroviral group (Machnik, et al., 2014).
Studies have recently confirmed that two out of three PERV
types, namely PERV-A and B, have been seen to replicate in
human cells during in-vitro research, meaning in a clinical setting.
To date, no PERV infection of human cells have been documented in-vivo, but the possibility of this occurring needs to be taken
into real account as new pathogens can be created at the point
of interaction, and these new pathogens can cause unpredictable damage (Prabha & Verghese, 2012).
Recent discoveries, however, have shown major advancements
in this area. Scientists have used CRISPR technology to successfully cut out sixty-two PERV sequences from a porcine genome.
The nuclei of these cells were then transferred into enucleated
pig oocytes by somatic cell nuclear transfer, and then implanted
into surrogate female pigs. The results were astonishing with
thirty-seven piglets being born, all with inactivated PERVs in the
genome. This research greatly expands the possibilities in the
realm of xenotransplantation, although other issues are yet to
be resolved (Denner, 2017).

The Issue of Rejection
With all the prementioned advantages, there are still barriers
preventing pig organ xenotransplantation from becoming the
standard medical procedure. Scientifically speaking, the biggest
barrier to overcome is the problem of rejection; the patient’s
natural response to an alien in the body. Firstly, within seconds
or minutes of the transplant, the possibility of hyperacute
rejection can happen. This type of rejection occurred when
pig organs were transplanted into nonhuman primates. The
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preformed antibodies of the receiver attached themselves to
the pig’s vascular endothelium and as protocol reaction to a
pathogen, the cascade system was initiated. This caused the endothelial cells to convert into procoagulant phenotypical cells,
resulting in hyperacute rejection. Attempts have been made to
prevent this by depleting the antipig antigens, or the complement system from the recipient’s serum, however, there are
still other forms of rejection that may occur. Acute humoral
xenograft rejection may occur during the first few days after the
transplant, and cellular rejection can become a problem even
weeks after the operation. This rejection is acute-cell mediated, meaning that different cells in the patient’s body recognize
the foreign organ as unfamiliar and begins to attack it. The cells
involved are usually the natural killer cells, macrophages, and
cytotoxic T cells. It is believed that even immunosuppressant
drugs cannot prevent this rejection from being triggered. If the
recipient is able to survive with the graft for a longer period of
time, chronic rejection may occur. The exact cause of this type
of rejection is not completely understood. However, the main
point regarding all types of rejections is that the antibodies or
killer-cells in the recipient attack the donated graft, resulting in
a slow, but ultimately fatal destruction of that organ (Esker &
Cooper, 2010). The information regarding the rejection or acceptance of a pig organ in a human patient is extremely limited,
as only a few procedures have been tested so far. The scientists
and doctors cannot study this further until a patient survives
the procedure for a longer time (McLean & Williamson, 2004).
Rejection of the organ can occur in any transplant, regardless
of whether the graft is from the same species or not. The difference is that in a xenotransplant rejection, the immunosuppressant drugs are not strong enough nor sophisticated enough to
significantly extend the patients survival time.

Potential Solution for Xenograft Reject
Genetic Engineering of the pigs is the newest and most successful method to date to prevent or mitigate the rejection of the
organ graft. One major advancement is the creation of a genetically engineered pig that expresses a human complement-regulatory protein. This protein is found in the pig’s vascular endothelial cells and protects the tissue of this donated organ from
being attacked by the pre-formed antibodies during hyperacute
rejection (Bloom, Moulton, McCoy, Chapman, & Patterson,
1999). Genetic engineers have also produced pigs which have
had the gene for α1,3-galactosyltransferase removed. The gene
for α1,3-galactosyltransferase codes for the production of the
enzyme that adds Galα1,3Gal oligosaccharides to different basic
glycoproteins and glycolipids in pigs. In general, Gal is a major
target for the human antibodies, as it is seen as a major invader.
The removal of this gene, and therefore the halt of the Gal production in the pigs, has significantly reduced the hyperacute rejections that usually occur during the pig to nonhuman primate
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xenograft trials (Esker & Cooper, 2010).
The results of this research have been positive; the length of
survival time increasing by the use of the genetically engineered
pig organs.A pig heart of this type lasted for 3-6 months, kidneys
for close to three months, and livers for days. The extension
of the survival period is proof of the success of the genetic
research (Esker & Cooper, 2010).
There are also genetic solutions being studied that will disable
the natural killer cells and the macrophages from attacking the
xenograft, although they have yet to be tested in pig to nonhuman-primate transplant. Genetic engineers are working on
producing pigs that are HLA-E or HLA-G transgenic as these
immunoregulatory molecules are expected to stop natural killer cell cytotoxicity (Esker & Cooper, 2010).

The Issue of Coagulation Dysregulation
Another barrier that has arisen during the xenotransplantation trials is the development of thrombotic coagulopathy and
consumptive coagulopathy, different types of coagulation dysregulation. Coagulation dysregulation is irregular blood clotting
in areas of the circulatory system. The xenograft recipient will
usually develop one of these, or possibly both, which poses a big
limitation to the survival time of the graft. In heart transplants
from genetically modified pigs to baboons, thrombotic coagulopathy is the predominant symptom, while in the kidney graft,
the baboon developed consumptive coagulopathy. It is thought
that physiological differences between pigs and primates are the
causes for these problems, although the exact reason for the
coagulation dysregulation development remains unclear. It is
known, however, that activated endothelial cells of the donated
organ are the cause for inflammation and coagulation in the
recipient. Ischemia, or inflammation, is inevitable in most types
of organ transplants, but various types of intertwined factors
can be the cause of graft endothelial cell activation (Cowan,
Robson, & d’Apice, 2011). One proposition suggests that the
endothelial cells activated by either the antibodies or the start
of the complement, increase the activity of TF, tissue factor.
The introduction of the TF into the portal vein activates the
instant blood-mediated inflammatory reaction, known as IBMIR.
Characteristics of IBMIR are platelet binding, complement activation, and thrombosis (Esker & Cooper, 2010).

Ethical Problems With Xenotransplantation
In addition to the biological barriers of Xenotransplantation,
problems regarding ethical and moral topics come into question
when researching the possibilities for the future.Transplantation
in general has a public risk associated with the administration of
immunosuppressant drugs.These drugs are known to lower the
patient’s ability to fight off infections, and therefore increase the
risk of contamination. For the patient, the risks involved need
to be weighed by their own physician; however there are public
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concerns involved as well.The new genetic engineering, plus the
previously used immunosuppressant drugs, have the potential to
“open the way for the emergence of new viral mosaics into the
general population” (Anderson, 2006).
The opposing side of the ethical debate brings up valid points
as well. With thousands of people in desperate need of organ
donations, is it ethically fair to deprive them of the possible solution that can potentially save so many lives? The introduction of
xenotransplantation can greatly reduce the waiting period for an
organ donation, and additionally provide the patient with a longterm graft. The immunosuppressant drugs have saved so many
people from death; is it morally okay to ban them on the slight
chance that they can cause an infection outbreak? These questions are some of the many that have come up in discussion over
the last couple of years, as the medical world is coming closer to
introducing this new phenomenon to regular medical protocol.
Another ethical problem involved in xenotransplantation is
the issue of personal privacy and confidentiality. This question
arises due to the necessity of monitoring of the patient after
an organ transplant, going as far as to institute a lifetime surveillance of the patient. This surveillance has become a part of
the system as an attempt to prevent pathogenic diseases from
spreading through organ transplant surgery. As previously discussed, the pathogenic risks involved in xenotransplantation are
very great and have caused medical outbreaks in the past. In
fact, in the year 2000, a hepatitis C breakout was reported due
to an infected donor that was mistaken to be healthy. Since
then, tremendous precautions have been taken while looking
for organ donors, as the transfer of pathogens through transplants can lead to numerous fatalities. Opponents of the monitoring system believe that this provision is an invasion of the
patients’ privacy, as well as the privacy of their family and friends.
Here lies the question whether or not the invasion of privacy
is considered to be ethical for the safety of the patien and the
“problem of maintaining ethical standards in situations such as
this is vexing” (Anderson, 2006).
The only possible way to effectively protect society from infectious diseases via xenotransplantation is if the national and international powers decide on a logical system, keeping the ethical
debates in mind. The World Health Organization has previously
come together to discuss this exact topic, although no agreement
was yet to be decided. To date, the only guidelines put in place
are those of the Food and Drug Administration’s Recombinant
DNA Advisory Council. The RAC approved gene recombination
studies to be done at Harvard and MIT, advancing the medical
research of this field. The RAC’s permission was granted with
the consent of the citizens of Massachusetts, justifying the ethical
questions involved in such research (Anderson, 2006).
The American Society of Transplant Physicians voice their
concern of infectious diseases being spread internationally. They
feel that United States regulations are not strong enough in

comparison to the severity of the risk involved. It is presently
legal for patients in need of an organ donation to receive organs from live donors living in impoverished countries, where
infections are known to be rampant. For example, there is a
website named Liver4you.org which arranges liver donations
from people in the Philippine Islands. Bringing these diseases
across to the United States through the organ transplant poses
as a major threat to the wellbeing of society (Anderson, 2006).
Often, doctors and surgeons are also researchers of new
xenotransplantation medication, which poses additional ethical
questions regarding the split between their medical responsibilities and their personal studies. The physicians can frequently
be confronted with “the well-being of the patient in direct opposition to the advancement of academic medicine” (Anderson,
2006). An example of what might result from such a situation
is a doctor convincing a patient to participate in a clinical trial
that he/she would otherwise not join. An infamous case of this
sort, known as the Baby Fae case, took place in 1984 when a
young child was used in a medical trial of a xenotransplantation
using a baboon heart. The parents were encouraged by optimistic doctors who hoped to provide the baby with “immediate
and long-term survival” but she only survived for four weeks
following the graft. Medical researchers have become cautious
getting involved in xenotransplantation studies in fear of this
sort of issue cropping up, in addition to the history of medical
science misconduct (Anderson, 2006).
Additionally, with the introduction of stem cells into the pig
embryo, the possibility of creating a pig with human elements
presents an ethical issue. The ethical debate discusses the possibility of human gametes to be created and an embryo to be
formed as an interspecies chimera. Although it is agreed upon
that the embryo would not be able to develop, the mere creation of it poses as an ethical question. Also, the differentiation
of human stem cells needs to be studied in depth as the question arises of what is stopping the stem cells from entering the
pig’s brain, or other areas, which will blur the margin of what is
considered human and what is considered animal? Is it morally
permissible to perform a procedure that can potentially give a
pig, human, high-level brain functions? These ideas are unlikely
in the scheme of things, but pose concerns in the biomedical
world nonetheless (Masaski & Nakauchi, 2017).

Conclusion
Scientific researchers are constantly trying to better the medical world; looking for solutions and applying their incredible
knowledge to helping humanity. The biomedical field is exploring the possibilities of genetic engineering combined with
stem-cell research, hoping for xenotransplantation to one day
become a standard medical procedure for patients with organ
failure. When it comes to genetic engineering, the possibilities
are endless; however, xenotransplantation has many barriers to
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overcome before it can become the standard medical procedure. However, the latest research may explore the best course
of action regarding this dynamic research. Researchers have
proposed for xenografts to be used for patients in the waiting
period that are waiting for an organ donor. This way, although
xenotransplantation is not yet a final solution, it will at least
minimize the number of deaths of patients, and the health risks
for waiting for a proper transplant. This change in proto-call
has the tremendous potential to save millions of lives, giving the
patient the ability to live the few months until they can receive
a proper transplant. Researchers are only beginning to uncover
the technology’s tremendous potential and long-term survival
of xenografts may be a few years away. Even so, it is possible that
for now, temporary xenotransplantation can be the life-saving
procedure that patients are hoping for (Servick, 2017).
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